Navigation Links
Crohns Disease Could Be Caused By Gaps In The Intestinal Barrier

The human bowel is lined with millions of projections called villi which increase the surface area of the intestine to allow for the efficient absorption of nutrients. The villi are covered in epithelial cells // which are constantly renewed – around a thousand billion cells are shed from the top of the villi every day.

Scientists found that this renewal process leaves 'gaps' in the lining of the bowel which, in healthy tissue, are immediately filled with a glue-like substance that plugs the gaps. This is in contrast to the previous assumption that the lining of the intestine was a continuous sheet of cells. The existence of gaps has been discovered for the first time and around 3% of the bowel's surface area is covered in this substance. It was previously assumed that the It is believed that gaps in the intestinal barrier could be a cause of inflammatory diseases of the gut such as Crohn's Disease, which could have important implications for the treatment. Crohn’s disease is an inflammatory bowel disorder that causes severe ulceration in the intestine, leading to pain, bleeding and diarrhoea.

It is suspected that patients with inflammatory disease may not have the same ability to plug the gaps left by the cell renewal process – meaning that bacteria can seep through the lining of the intestine. The research may also explain the development of colon cancer as a result of failure in the renewal process of epithelial cells.

Understanding this cell shedding process may lead to new treatments for inflammatory bowel disease and perhaps even colon cancer in future.

'"/>




Page: 1

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
2. Vitamins-The answer to Heart Disease?
3. Link between Constipation and Parkinsons Disease
4. Levels Of Blood Proteins May Help Heart Disease Care
5. New Drug PP188 Helps Sickle Cell Disease
6. Gene Treatment for Heart Disease
7. Legume Consumption Can Cut Heart Disease Risk
8. Link Between Infection And Heart Disease
9. Celiac Disease in Type 1 Diabetes
10. Shunt for Alzheimers Disease
11. High iron levels may cause Cardiovascular Disease in women
Post Your Comments:
(Date:12/2/2008)... , National Non-profit La...that Provides Eye Exams at No Cost to Eligible Pat... San Francisco, CA (Vocus) December 2...eniors who suffer with an eye disease known as Age...always, "No.", , , , ,Picture this&hell...
(Date:12/2/2008)... , Liberty Mutual Provide...ms at www.BeFireSmart.com , ...ty Mutual Insurance and Holly Robinson Peete , a...ming up to encourage families to set aside a few m...ty precautions and response plans at BeFireSmart.c...
(Date:12/1/2008)... SOUTH BEND, Ind., Dec. 2 Patient...cilities are on the rise according to a new report...atient Pulse Report: Patient,Perspectives on Amer...,facilities as a driver for improvement in patien...ore than 2 million patients treated at more than,...
(Date:12/1/2008)... , CHICAGO New research has found that the avail...phy (CT) scanner in an emergency room can signific...ceive a potentially life-saving treatment. Results...nter (NSMC)-Salem Hospital in Salem, Mass., will b...iological Society of North America (RSNA). , "T...
Breaking Medicine News(10 mins):Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 2Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 3Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 2Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 3Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 4Health News:Outpatient Service Facilities Face Increasing Competition - Patient Perceptions More Important Than Ever 2Health News:Portable CT increases chance of stroke survival and recovery 2
...udy shows the anti-inflammatory drug naproxen may ...a non-steroidal anti-inflammatory drug (NSAID) com...y and arthritic conditions. Researchers in Quebec ...Ds //in the prevention of acute myocardial infarct...
...cessfully used gene therapy to restore sight to an...eam of scientists led by Jean Bennett, at the Univ...this month's Nature Genetics.Their experiment invo...a form of blindness, that also affects human infan...
...hicago, studied the use of a ginseng extract for t...een shown to have many beneficial effects on healt...he condition affects about 8% of the U.S. populati...he vast majority of people with diabetes more than...
...t that acupuncture is at least as safe as conventi...n the safety of complementary and alternative medi... one of the first serious safety assessments on ac...d physiotherapists carrying out acupuncture agreed...
Other Medicine News:
(Date:12/1/2008)...Dec. 1 Genaera Corporat...of subjects has begun in study MSI-1436C-102 (Stud... of trodusquemine (MSI-1436) in overweight and obe...ic for the treatment of type 2 diabetes and obesit...te insulin and leptin pathways through the highly ...
(Date:11/30/2008)...c. 1 Older adults who e...ow and a greater number of small blood vessels in ...t the annual meeting of the Radiological Society o...ducted at the University of North Carolina ( UNC...ans of older adults who exercise to brain scans of...
(Date:11/26/2008)...26 Children whose eyes ...tly increased risk of developing mental illness by... Clinic study published this month in Pediatrics ,...ediatrics. , , The retrospective study exam...bismus (misaligned eyes) and compared them with re...
(Date:11/25/2008)...pondents against expanding statin use broadly in w..., N.J., Nov. 25 JUPITER, a clinica...iovascular risk of healthy patients with elevated ...er adults, according to a national poll directed a...ok part in the online poll conducted by medical ne...
Breaking Medicine Technology:Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Eye Divergence in Children Triples Risk of Mental Illness 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Dallas Among the First to Offer Probiotic Supplement Align 28R 29 6984 1Dallas Among the First to Offer Probiotic Supplement Align 28R 29 6984 2Dallas Among the First to Offer Probiotic Supplement Align 28R 29 6984 3VH1 Teams Up with Dr Drew for Celebrity Rehab With Dr Drew a Series Depicting the Process of Overcoming Addiction 6979 1VH1 Teams Up with Dr Drew for Celebrity Rehab With Dr Drew a Series Depicting the Process of Overcoming Addiction 6979 2VH1 Teams Up with Dr Drew for Celebrity Rehab With Dr Drew a Series Depicting the Process of Overcoming Addiction 6979 3A young star in childhood cancer research 6974 1Undocumented Hispanics Less Likely to Use U S Health Care Services 6972 1Undocumented Hispanics Less Likely to Use U S Health Care Services 6972 2
...07 – On 23 July SYGNIS Pharma,AG will presen...AX200 (AXIS-study)., AX200, a compound for the tre...ate in SYGNIS’ product pipeline. The,primary...ty of,AX200 in acute stroke patients. The results ...ion for the further clinical,development of AX200....
...swire-FirstCall/ -- ImClone,Systems Incorporated a...sults from an open-label Phase III study of ERBITU...the first-line,treatment for metastatic non-small ...ts primary endpoint of progression-free,survival (...w,committee (IRRC). However, key secondary endpoin...
Other Medicine Technology:Sygnis Pharma AG announces date for presentation of clinical,results 2Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer 2Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer 3Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer 4Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer 5Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer 6Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer 7Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer 8Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer 9
Solid 8 mm blades. Dull finish. Most popular size or model.
Open 10 mm blades. Dull finish.
Open 14 mm blades of heavy 1 mm wire. Dull finish. Most popular size or model.
Fenestrated 14 mm blades. Self-locking mechanism. Dull finish.
Medicine Products: